Amy Rudolph

Amy Rudolph is a seasoned professional in the pharmaceutical industry with over two decades of experience.

In her current role as the Global Head of Evidence and Launch Excellence at Novartis, Amy focuses on developing comprehensive evidence strategies to support regulatory, reimbursement, and provider adoption success globally.

Throughout her career, Amy has held various key positions at Novartis, where she led initiatives in medical access, health economics, outcomes research, and specialized in heart failure programs.

Amy's expertise extends across a range of therapeutic areas, including hypertension, atherosclerosis, and stroke.

She has a strong background in research and development, having published patents and articles covering preclinical research, clinical trials, and outcomes research.

Amy's academic journey includes post-doctoral fellowships in Biological Chemistry and Hematology/Oncology, as well as a Ph.D. in Biochemistry and Molecular Biology.

Her solid educational foundation began with a Bachelor's degree in Biology.

Amy's professional accolades include participation in prestigious leadership programs and receiving the Tribute to Women in Industry (TWIN) award.

With a wealth of experience in medical affairs, research, and leadership, Amy Rudolph is a highly respected figure in the pharmaceutical industry.